Search Results - "Gunzer, K"

REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours by Lévy, C., Allouache, D., Lacroix, J., Dugué, A.E., Supiot, S., Campone, M., Mahe, M., Kichou, S., Leheurteur, M., Hanzen, C., Dieras, V., Kirova, Y., Campana, F., Le Rhun, E., Gras, L., Bachelot, T., Sunyach, M.-P., Hrab, I., Geffrelot, J., Gunzer, K., Constans, J.-M., Grellard, J.-M., Clarisse, B., Paoletti, X.

“…Brain metastases (BMs) are associated with a poor prognosis. Standard treatment comprises whole-brain radiation therapy (WBRT). As neo-angiogenesis is crucial…”
Get full text

1874 Phase 1b/2 study results for masitinib plus gemcitabine and carboplatin in advanced triple negative breast cancer by Campone, M, Ferrero, J.M, Gunzer, K, Priou, F, Dubreuil, P, Mansfield, C, Moussy, A, Hermine, O

Get full text

REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours by Lévy, C, Allouache, D, Lacroix, J, Dugué, A E, Supiot, S, Campone, M, Mahe, M, Kichou, S, Leheurteur, M, Hanzen, C, Dieras, V, Kirova, Y, Campana, F, Le Rhun, E, Gras, L, Bachelot, T, Sunyach, M-P, Hrab, I, Geffrelot, J, Gunzer, K, Constans, J-M, Grellard, J-M, Clarisse, B, Paoletti, X

Get full text

IBRUTINIB IN ASSOCIATION WITH R‐DHAP/OX FOR PATIENTS WITH RELAPSED/REFRACTORY B‐CELL LYMPHOMA: PRELIMINARY RESULTS OF THE BIBLOS PHASE IB LYSA STUDY by Bonnet, C.M., Lamy, T., Fruchart, C., Legouill, S., Gunzer, K., Gastinne, T., Jardin, F., Karlin, L., Houot, R., Dupuis, J., Tilly, H., Salles, G.

Get full text

3006 Predictive factors for toxicity of non platinum chemotherapy by Lheureux, S, Launay-Vacher, V, Allouache, D, Gunzer, K, Delcambre, C, Rivière, A, Bouhier, K, Dupont, M, Grossi, S, Joly, F

Get full text

117P Pretherapeutic neutrophil-lymphocyte ratio as prognostic and predictive factors in metastatic breast cancer treated with cyclin dependent kinase 4/6 inhibitors by Rottier, P., Da Silva, A., Levy, C., Allouache, D., Johnson, A.C., Hrab, I., Faveyrial, A., Gunzer, K., Segura Djezzer, C., Morel, A., Villemin, M., Boscher, C., Boismoreau, L., Cherifi, F., Lequesne, J., Emile, G.

Get full text

4005 ORAL An open label randomized Phase II study of oral triple angiokinase inhibitor BIBF 1120 in Hormone Refractory Prostate Cancer (HRPC) patients who progressed after docetaxel by Oudard, S, Chevreau, C, Fléchon, A, Gunzer, K, Houédé, N, Krakowski, I, de Mont-Serrat, H, Rouyrre, N, Kaiser, R, Droz, J.P

Get full text

19P HER2-low prognosis in early breast cancer: A CANTO based study (LILAC) by Durand, L., Cherifi, F., Emile, G., Blanc-Fournier, C., Morel, A., Johnson, A.C., Rottier, P., Hrab, I., Desbois, P., Boscher, C., Levy, C., Dubot, C., Gunzer, K., Bimont, B., Segura-Djezzar, C., Allouache, D., Lequesne, J., Christy, F., Da Silva, A.

Get full text

Corrections to “REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours” by Lévy, C., Allouache, D., Lacroix, J., Dugué, A.E., Supiot, S., Campone, M., Mahe, M., Kichou, S., Leheurteur, M., Hanzen, C., Dieras, V., Kirova, Y., Campana, F., Le Rhun, E., Gras, L., Bachelot, T., Sunyach, M.-P., Hrab, I., Geffrelot, J., Gunzer, K., Constans, J.-M., Grellard, J.-M., Clarisse, B., Paoletti, X.

Get full text

Addition of BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2, to letrozole in estrogen receptor (ER)-positive metastatic breast cancer (mBC) progressing on letrozole monotherapy by Gunzer, K., de Mont-Serrat, H., Uttenreuther-Fischer, M. M., Misset, J.

“…Abstract only…”
Get full text

IMAGE, a randomized phase Ib/II study of elisidepsin in pretreated advanced gastroesophageal cancer by Szyldergemajn, S. A., Gonçalves, A., Metges, J. P., Gunzer, K., Montagut, C., Salazar, R., Alsina, M., Evans, T. R. J., Swinson, D., Petty, R. D., Singer, H., Kahatt, C. M.

“…Abstract only…”
Get full text

Is it possible to predict nonplatinum chemotherapy-related toxicity? by Lheureux, S., Launay-Vacher, V., Gunzer, K., Delcambre, C., Bouhier, K., Kaluzinski, L., Ngo, M., Maron, D., Zalcman, G., Joly, F.

“…Abstract only…”
Get full text

Follow-Up after Treatment of Localized Breast Cancer: Impact of a Planned Screening for the Diagnosis of Relapse in a Cohort of 484 Patients (Pts) by Lévy, C., Allouache, D., Delcambre, C., Switsers, O., Ollivier, J., Gunzer, K., Riviere, A., Berthet, P., Segura, C., Toudic-Emily, F., Blanc-Fournier, C., Delozier, T.

“…Abstract Background: after a localized breast cancer, none study demonstrates any benefit on survival from extensive follow-up, so international guidelines…”
Get full text

Evaluation of current practice: management of chemotherapy-related toxicities by Lheureux, Stéphanie, Clarisse, Bénédicte, Launay-Vacher, Vincent, Gunzer, Katharina, Delcambre-Lair, Corinne, Bouhier-Leporrier, Karine, Kaluzinski, Laure, Maron, Dominique, Ngo, Minh-Dung, Grossi, Sara, Dubois, Brice, Zalcman, Gérard, Joly, Florence

“…Adverse effects induced by cytotoxic chemotherapy (CT) have been mostly evaluated in clinical trials. The aim of this study was to assess in a nonselected…”
Get full text

Addition of BIBW 2992, an Irreversible Inhibitor of EGFR/HER1 and HER2 Inhibitor, to Treatment Continuation of Letrozole in Estrogen Receptor (ER-) Positive Metastatic Breast Cancer Progressing on Letrozole by Gunzer, K., Joly, F., Delozier, T., Ferrero, J., Largillier, R., Gligorov, J., de-Mont-Serrat, H., Uttenreuther-Fischer, M., Solca, F., Bell, S., Stopfer, P., Bousquet, G., Misset, J.

“…Abstract Background: The mechanisms of acquired hormone-resistance may involve cross-talk between the estrogen receptor (ER) and human epidermal growth factor…”
Get full text

Prognostic factors for survival of metastatic breast cancer (MBC): A retrospective study from 4,233 women treated in a single institution by Lévy, C., Switsers, O., Ollivier, J., Allouache, D., Delcambre, C., Génot, J., Gunzer, K., Toudic-Emily, F., Segura, C., Delozier, T.

“…Abstract only…”
Get full text

TEMP/TDM et scintigraphie osseuse en cancérologie : impact d’une acquisition scannographique basse dose chez les patients avec foyer isolé suspect ou de nature indéterminée by Franson, T., Bardet, S., Loiseau, C., Switsers, O., Allouache, D., Allouache, N., Gunzer, K., Aide, N.

“…Évaluation de l’apport de la TEMP/TDM basse dose et de la valeur ajoutée d’une acquisition « diagnostique » centrée chez les patients présentant un foyer isolé…”
Get full text